Analysis

Briefings

Subscribe to Briefings

Critical Crops; Patent Claims on Cloning

Sunday 1st June 1997

Will governments opt for a multilateral system of crop germplasm exchange or will they determine to pursue bilateral agreements between countries and companies? RAFI examines Africa's bargaining position, and concludes that bilateral negotiations over crop germplasm will benefit the North, at the expense of food security in the South.

Gene Licensing Agreements; Precision Farming

Tuesday 1st April 1997

Two trends in industrial agriculture are contributing to the erosion of farmers' rights and lead to bioserfdom: 1) Monsanto's 1996 gene licensing agreement; 2) "Precision farming" and the role it plays in the commodification of information technology and the growing influence of the life industry in farm-level decision-making.

Saturday 15th February 1997

This map illustrates the transfer of human tissues through third countries. This graphic is part of the Communique on Human Tissue Trade.

 

 

The Global Traffic and Market in Human Biomaterials

Saturday 1st February 1997

Despite the promise of medical breakthroughs, the utilization of human tissue prompts intense ethical concerns regarding ownership of human biomaterials, eugenics, discrimination and medical confidentiality. A large and growing South to North and North to North movement of human tissue is taking place in an almost total policy and regulatory vacuum.

Bolivian Quinoa Claimed in US Patents

Monday 30th December 1996

"Biopiracy" -- a term coined by RAFI in 1994 - refers to the use of intellectual property laws to gain exclusive monopoly control over genetic resources that are based on the knowledge and innovation of farmers and indigenous peoples. This issue examines a patent claim on Bolivian quinoa, a US patent on turmeric, and more.

New IPR Resource Kit Available. U.S. Equivocates on Hagahai Patent

Monday 30th September 1996

This is RAFI's first annual update on the "Life Industry" - the giant transnational enterprises that use, buy, sell and control an ever-growing market share of bio-industrial products relating to food, agriculture and health. A list of the top 10 corporations, ranked by 1995 sales, is given for each sector.

Cotton "Failing in the Field"

Thursday 1st August 1996

Pharmaceutical firms and biotech companies are approaching botanical gardens to buy samples of tropical plant diversity - a clear violation of the spirit - if not the law - of the Convention on Biological Diversity. The rights of farmers and indigenous peoples are being bypassed by corporate deals that make a mockery of the CBD's fundamental principles.

Monday 1st April 1996

Human Tissue Collection Initiatives by the U.S. Military; Colombian Indigenous Peoples' Cells in the U.S.; Accompanying maps showing cell collections inColombia and Papua New Guinea

Crucial Decisions in 1996. The Real Hot Spots.

Thursday 1st February 1996

RAFI's survey of agricultural biodiversity reveals that 75% of ex situ genetic resources and technology are held in the North, while 83% of in-situ genetic resources and technology are held in the South. Multilateral regimes for agricultural biodiversity management must insure that proceeds from biodiversity benefits go to the South's farmers.

Bio-Prospectors Hall of Shame...or Guess Who's Coming to Pirate Your Plants?! Pros and Cons of Bilateral Bioprospecting Agreements

Tuesday 26th December 1995

ISSUE: Biodiversity prospecting is the exploration, extraction and screening of biological diversity and indigenous knowledge for commercially valuable genetic and biochemical resources. Bilateral bioprospecting agreements are sanctioned by the multilateral Convention on Biological Diversity. In the vast majority of cases, however, commercial bioprospecting agreements cannot be effectively monitored or enforced by source communities, countries, or by the Convention, and amount to little more than "legalized" bio-piracy.

Pages

Reports

Subscribe to Reports

The Intellectual Property Challenge to Public Agricultural Research and Human Rights and 28 Alternative Initiatives

Saturday 30th September 2000

Given their current governance structure, CGIAR has neither the competence nor the accountability to be entrusted with intellectual property (IP) or public/private policy decisions. Immersed in their work and the struggle to survive, they have taken the path of least resistance and followed the IP trail. RAFI suggests at least 28 specific policy initiatives that the public sector should consider as alternatives to IP. A 33 page document.

Seminis Eliminates 2,000 Varieties

Monday 17th July 2000

Seminis, the world s largest vegetable seed corporation, announced that it would eliminate 2,000 varieties or 25% of its total product line as a cost-cutting measure. Seed industry consolidation is dramatically narrowing the availability of non-hybrid vegetable varieties and a wealth of seed diversity is being lost forever.

Oil on Troubled Waters...or just a Tempest in a Test-tube?

Wednesday 12th April 2000

In 1980 the U.S. Supreme Court narrowly voted to allow the patenting of a living microorganism intended to soak up oil spills.  The decision ushered in a new era in intellectual property.  Suddenly, the products and processes – even the formulae - of life became patentable.  From microorganisms, patent offices have soldiered on to grant exclusive monopolies for plants, animals, entire species, human cell lines, and even fragments of human DNA that only Computers have seen and no one has understood. 

Unholy Alliance - Corporate Cristi at the Vatican

Tuesday 23rd November 1999

The Vatican's endorsement of GM foods leaves many wondering how it can justify it's faith in the food industry given recent events.

For content related to the specific item being viewed or tasks at hand e.g. "Similar content" and search results

 

 

Subscribe to Briefings Subscribe to Reports